Full speed ahead for Vytorin II at Merck, Schering

The disastrous results of the recent Vytorin study have apparently done nothing to blunt the appetites of Merck and Schering-Plough for a follow-up therapy that is designed to work--or not work--in much the same way. Spokesmen for both companies tell Dow Jones that it is full speed ahead for a program to develop a similar cholesterol pill that combines Vytorin and a generic Lipitor as they looks to expand their command of the $32 billion market for cholesterol drugs.

Researchers released data earlier this week showing that Vytorin failed to perform better at reducing the rate of artery clogging than a generic statin, even though the drug reduced greater levels of bad cholesterol. Scientists at the Big Pharma companies are planning to complete studies on a Zetia-atorvastatin (Lipitor) combo so they can begin marketing it when the blockbuster Lipitor loses patent protection in 2010. AstraZeneca and Abbott are also both working away at a new combo cholesterol pill.

- here's the Dow Jones report

ALSO: Day three of chatter about Vytorin's poor performance in the ENHANCE study, and the furor seems to be increasing. Report

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.